Non-Invasive Prenatal Testing involves replacing invasive testing methods, which pose serious risks to developing fetuses. Non-Invasive Prenatal Testing (NIPT) is an emerging technology, which can be performed within 9 weeks of pregnancy and involves no risk of miscarriage. In addition, it offers clinical benefits over existing prenatal screening tests, such as maternal serum screening (MSS), by detecting the presence of trisomy 21 (Down syndrome, DS) with high sensitivity (99.9%) and specificity (98%). Moreover, there are several campaigns and programs conducted to spread awareness regarding Non-Invasive Prenatal Testing (NIPT) for the early detection of genetic abnormalities. This, in turn, contributes to growth of the Non-Invasive Prenatal Testing market.
The Non-Invasive Prenatal Testing (NIPT) Market is segmented on the basis of Product Types, Method, Application and region.
Major Product Types of Non-Invasive Prenatal Testing (NIPT) Market covered are:
- Consumables
- Instruments
- Services
Major Methods of Non-Invasive Prenatal Testing (NIPT) Market covered are:
- Biochemical Screening Tests
- Ultrasound Detection
- Cell-Free DNA in Maternal Plasma Tests
- Fetal Cells in Maternal Blood Tests
Major Applications of Non-Invasive Prenatal Testing (NIPT) Market covered is:
- Trisomy
- Microdeletion Syndrome
Increasing developmental strategies by key players, such as agreements, collaborations, and new product launches, in different regions are promoting market growth. For instance, in April 2019, Thermo Fisher Scientific and NX Prenatal Inc. entered into a collaboration for the development of clinical mass spectrometry-based proteomics assays to monitor maternal & fetal health during pregnancy and provide noninvasive risk assessments of pregnancy outcomes. Similarly, some key players are focusing on providing access to comprehensive NIPT solutions across various regions. For instance, in June 2019, BGI Genomics and Eluthia launched BGI’s leading non-invasive prenatal test, NIFTY in Germany. The test screens for trisomies 21, 18, 13 with a sensitivity rate of over 99%. In addition, it also has additional screening options for 93 other trisomies, sex chromosomal aneuploidies, and deletion/duplication syndromes.
No comments:
Post a Comment